IQVIA Holdings Inc. (IQVIA) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries.
IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. The company is committed to using artificial intelligence (‘AI’) responsibly, ensuring...
IQVIA Holdings Inc. (IQVIA) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries.
IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI, advanced analytics, the latest technologies and extensive domain expertise. The company is committed to using artificial intelligence (‘AI’) responsibly, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, the company is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
The company is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. The company’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.
The company is one of the largest and most comprehensive collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales, prescription and promotional data, medical claims, electronic medical records, genomics, and social media. The company’s scaled and growing information set contains approximately 64 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally. Based on this data, the company delivers information and insights on approximately 90% of the world’s pharmaceuticals, as measured by 2023 sales. The company standardizes, curates, structures and integrates this information by applying its sophisticated analytics and leveraging its global technology infrastructure. This helps the company’s clients run their organizations more efficiently and make better decisions to improve their clinical, commercial and financial performance. The company has developed a comprehensive portfolio of intelligent, actionable information offerings over a period of many years through innovation, expertise and hard work that differentiates its capabilities to support customers throughout the world.
The company combines its proprietary information assets with advanced analytics, transformative technology and domain expertise to develop clinical and commercial capabilities that enable the company to grow its relationships with healthcare stakeholders throughout the life science’s value chain.
Growth Strategy
The key elements of the company’s strategy are continuing to innovate through the company’s IQVIA Connected Intelligence by leveraging its information, advanced analytics, transformative technology, and significant domain expertise; building upon the company’s extensive client relationships and leverage its global presence; expanding the penetration of the company’s offerings to the broader healthcare marketplace; and expanding portfolio through strategic acquisitions.
Segments
The company operates through three reportable segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Their offerings complement each other and can provide enhanced value to the company’s clients when delivered together, with each driving demand for the other. Their offerings complement each other and can provide enhanced value to the company’s clients when delivered together, with each driving demand for the other.
Technology & Analytics Solutions segment
This segment provides mission critical information, technology solutions and real-world insights and services to the company’s life science clients.
The company’s Technology & Analytics Solutions offerings include:
Technology platforms: The company provides an extensive range of cloud-based applications and associated implementation services. SaaS solutions that support a wide range of commercial and clinical processes, including customer relationship management (‘CRM’), performance management, real-world evidence generation, compliance and safety reporting, incentive compensation, territory alignment, roster management, call planning, multi-channel marketing, and master data management. These solutions are used by healthcare companies to manage, optimize and execute their clinical and commercial strategies in an orchestrated manner while addressing their regulatory obligations. Using proprietary algorithms, the company combines its country-level data, healthcare expertise, and therapeutic knowledge in over 100 countries to create its Global Market Insight family of offerings, such as MIDAS, Analytics Link and Disease Insights, which provides a leading source of insight into international market dynamics and are used by most large pharmaceutical companies.
Real World Solutions: The company enables life sciences and provider customers to generate and disseminate evidence in a cost-efficient manner which informs health care decision making and ultimately improves patients’ outcomes. The company uses of a wide range of privacy and security safeguards protect non-identified patient-level medical claims, prescriptions, electronic medical records, genomics, patient reported outcome and social media data. The company’s scaled information networks include more than 1.2 billion unique non-identified patient records globally, as well as access to profiles of over 4,100 real world data assets in more than 100 countries uniquely facilitating data discoverability for healthcare research via the IQVIA Health Data Catalog. The company’s technology-enable these data flows by harmonizing them to common data models and loading them onto its proprietary evidence platforms for secure access by its customers. The company provides access to deep clinical data in Oncology, Rare Disease, and other specialty areas. The company’s Natural Language Processing capabilities help it creates structured data from unstructured clinical notes and the published literature and provide accredited independent medical educational content. The company helps its global customers across payers, providers, governments, and biopharmaceutical companies to answer critical questions about healthcare interventions related to safety, effectiveness, and value. The company also brings together stakeholders across healthcare to collaborate in efforts to develop new information sources, more effective reimbursement models, and better patient outcomes.
Analytics and consulting services: The company provides a broad set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services to help the commercial operations of life sciences companies successfully transform their commercial models, engage more effectively with healthcare stakeholders and reduce their operating costs. The company also help its client’s research and development function to address strategic challenges in the drug development process. The company’s global teams leverage local market knowledge, deep scientific and therapeutic area expertise and its global information resources to assist its clients with research and development strategy, portfolio, brand and commercial strategy, as well as pricing and market access and launch excellence.
Information offerings: The company’s national offerings comprise unique services in over 100 countries that provide consistent country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment and promotional activity across multiple channels including retail, hospital and mail order. The company’s sub-national offerings comprise unique services in over 70 countries that provide a consistent measurement of sales or prescribing activity at the regional, zip code and individual prescriber level (depending on regulation in the relevant country). The company’s widely used reference database tracks over 25 million healthcare professionals in over 100 countries, providing a comprehensive view of health care practitioners that is critical for the commercial success of its clients’ marketing and sales initiatives.
Research & Development Solutions
This segment, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services.
The company’s Research & Development Solutions offerings include:
Project Management and Clinical Monitoring: Drawing upon the company’s years of experience, it sites databases, its site relationships and its highly trained staff, its solutions and services enables the efficient conduct and coordination of multi-site clinical trials (generally Phase II-IV). The company’s service offerings include protocol design, feasibility and operational planning, site start up, patient recruitment, and clinical site monitoring. By infusing technology into field-based monitoring, the company is able to reduce data collection steps and time.
Clinical Trial Support Services: Each clinical trial requires a number of concurrent services and data streams. The company offers a broad range of functional services and consultation to support clinical trials through specialized expertise that help clients efficiently collect, analyze, and report the quality data and evidence they need to gain regulatory approval.
Laboratory Services: The company provides its clients globally scaled end-to-end clinical trial laboratory and research services. The company’s offerings include the full range of central laboratory, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker laboratory services along with sample and consent tracking services.
Strategic Planning and Design: By bringing the company’s data science capabilities to its strategic planning and design services, it offers consultation services to improve decisions and performance including portfolio, program and protocol planning and design, biomarker consultation, benefit-risk management, regulatory affairs, biostatistics, modeling and simulation, and personalized medicine.
Patient and Site Centric Solutions: A comprehensive suite of technology and site support services which create custom strategies to engage and retain patients. Included is the company’s site management organization Avacare Clinical Research Network, which orchestrates the activities of over 200 investigators and extends solutions to patients across more than 20 therapeutic indications in nearly 40 locations. Additionally, the company’s decentralized approaches and technologies support sites and sponsors through direct-to-patient recruitment, remote nursing, data entry, and study coordinator resources. The company’s solutions reduce study burden and foster a supportive, patient-centric journey.
Contract Sales & Medical Solutions
This segment provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market.
The company’s Contract Sales & Medical Solutions offerings include:
Health Care Provider Engagement Services: The company partners with biopharmaceutical companies and other life sciences providers (e.g., medical device companies) to develop and deploy tailored stakeholder engagement solutions, including contract sales and market access professionals, which are focused on product sales and improving brand value at all stages of the product lifecycle from initial market entry to brands nearing patent expiry.
Patient Engagement Services: The company’s nurse-based programs directly engage with patients to help improve their disease and medication understanding through interventional and non-interventional support, while also providing assistance in navigating complex reimbursement coverage issues. The company’s patient engagement services combine insight from clinical trials and social listening, behavioral design, personal and innovative eHealth multichannel interactions across multiple sites (e.g., the physician’s office, hospital, pharmacy, home), that act as an extension of the Health Care Provider prescribed treatment course which can lead to improved adherence and better overall outcomes.
Medical Services: The company provides a range of medical services and scientific strategy to help biopharmaceutical companies plan and transition from the clinical trial setting to commercialization. Beginning in the clinical trial stage, the company services can deploy educators to clinical trial sites to accelerate patient recruitment and improve retention, assist in translation of complex clinical trial data into a compelling scientific platform and publication strategy, and provide field medical teams to facilitate scientific engagement with key opinion leaders and healthcare decision makers, before and after product approval.
Clients
Sales to companies in life sciences, including pharmaceutical companies, biotechnology companies, device and diagnostic companies, and consumer health companies, account for the majority of the company’s revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, and many of these companies subscribe to reports and services in many countries. Other clients include payers, government and regulatory agencies, providers, pharmaceutical distributors, and pharmacies. For the year ended December 31, 2024, the largest client based on its percentage of total company revenues contributed approximately 5%.
Competition
Technology & Analytics Solutions
The company’s offerings compete with various firms, including Accenture, Aetion, Panalgo (a Norstella company), Cognizant Technology Solutions, Deloitte, Pharmaceutical Product Development, Inc. (part of Thermo Fisher Scientific Inc.), Relx, IBM, Infosys, Oracle Health, McKinsey, NielsenIQ, Optum Insight (part of UnitedHealth Group), Parexel International Corporation, Press Ganey, RTI Health Solutions, ICON plc, Definitive Healthcare, Cegedim, Tempus, Merative, CompuGroup Medical, Medidata (Part of Dassault Systèmes), Clarivate, Veeva, and ZS Associates.
Research & Development Solutions
Some of the company’s larger competitors include ICON plc, Parexel International Corporation, Pharmaceutical Product Development, Inc., and Syneos Health, among others.
Contract Sales & Medical Solutions
Contract Sales & Medical Solutions’ primary competitors in the United States are Syneos Health, Amplity Health, Eversana and Inizio. Outside of the United States, Contract Sales & Medical Solutions typically competes against single country or more regionally focused service providers, such as Inizio, Syneos Health, EPS Corporation, Uniphar, and CMIC HOLDINGS Co., Ltd.
Government Regulation
Certain of the company’s services are subject to the FDA’s regulations against ‘off-label promotion,’ which require sales representatives to restrict promotion of the approved product they are detailing to the approved labeling for the product.
Additionally, the company’s United States laboratories are subject to applicable federal and state laws and regulations and licensing requirements relating to the handling, storage and disposal of hazardous waste, radioactive materials and laboratory specimens, including the regulations of the Environmental Protection Agency, the Nuclear Regulatory Commission, the Department of Transportation, the National Fire Protection Agency and the United States Drug Enforcement Administration (‘DEA’). The use of controlled substances in testing for drugs with a potential for abuse is regulated in the United States by the DEA and by similar regulatory bodies in other parts of the world. The company’s United States laboratories using controlled substances for testing purposes are licensed by the DEA. The regulations of the United States Department of Transportation, Public Health Service and Postal Service apply to the surface and air transportation of laboratory specimens. The company’s laboratories also are subject to International Air Transport Association regulations, which govern international shipments of laboratory specimens.
Intellectual Property
The company’s registered or applied for registration for certain of these trademarks, including IQVIA, in the United States and other jurisdictions and aggressively seek to protect them.
History
The company was formerly known as Quintiles Transnational Holdings Inc. and changed its name to Quintiles IMS Holdings, Inc. in 2016. Further, the company changed its name to IQVIA Holdings Inc. in 2017.
